Leadership team

LGC’s board and executive management teams have an extensive understanding of the scientific marketplaces we serve. They are committed to supporting and creating opportunities for our employees worldwide, delivering high quality performance and services for our customers.

Board of directors

Tim Robinson CBE - Non-Executive Chair
Tim Robinson

Tim Robinson CBE - Non-Executive Chair

Tim joined LGC in May 2013 as Chief Executive Officer. In September 2021, he stepped down from that role and was appointed Non-Executive Chair of the Board.

Tim has followed an international career in the technology and science sectors, spanning engineering, commercial and corporate leadership. Following a decade with IBM in Asia and Europe, Tim held senior executive positions in Silicon Graphics (SGI) and Thales, prior to being CEO for Xafinity, the privatised Office of the Paymaster General, and subsequently to Talaris (ex De La Rue). Tim is a Non-Executive Director of the UK Home Office. He has also been a Non-Executive Board Member of The UK Government Department for International Development, UK Trade & Investment, a Member of the Association of Oxfam, serving on their Audit Committee, and a Non-Executive Director of Camelot Group.

Tim was awarded a CBE in the 2020 New Year’s Honours list for his advisory role in a personal capacity to the UK Government.

Euan O’Sullivan - President and Chief Executive Officer
Euan

Euan O’Sullivan - President and Chief Executive Officer

Euan was appointed President and Chief Executive Officer in September 2021.

After joining LGC in 2007 as a Non-Executive Director, Euan served as Corporate Development Director from July 2010 before being appointed Managing Director of the Standards division in 2012. In 2017, he joined the Board of LGC as an Executive Director and was then appointed Chief Operating Officer (COO) in June 2020.

Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan worked as a Consultant in Accenture’s business strategy practice and within the M&A division of Close Brothers Corporate Finance. Euan is a graduate of University College, Oxford.

Vivid Sehgal - Chief Financial Officer

Vivid Sehgal - Chief Financial Officer

Vivid joined LGC as Chief Financial Officer on 24 January 2022, from Tate & Lyle Plc, a global ingredients and solutions company.

Prior to this, he served as CFO of Delphi Technologies Plc and LivaNova Plc and led both companies through their public listings. Earlier in his career, he held senior management positions in Allergan Inc., Gillette Inc., and GlaxoSmithKline Plc in the US, Europe and the Middle East.

Vivid is a member of the Chartered Institute of Management Accountants and holds a Master’s Degree in Finance from the University of Exeter.

Dr Derek Craston - Chief Scientific Officer

Dr Derek Craston - Chief Scientific Officer

Derek joined the Board of LGC on 1 February 2012 as Chief Scientific Officer.  He continues with his existing role leading LGC's National Measurement Laboratory and Nucleic Acid Therapeutics (NAT) operations.

Derek's responsibilities as CSO include leading the scientific efforts of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Tish S Creasey, PhD - Non-Executive Director

Tish S Creasey, PhD - Non-Executive Director

Tish joined the Board of LGC in August 2020. 

Prior to joining the Group, Tish served as the Execute Vice President of Applied Solutions Strategy, Marketing and Innovation (SMI) for MilliporeSigma, a Merck KGaA Company.  Before the acquisition of Sigma-Aldrich by Merck KGaA, Tish was part of Sigma-Aldrich from 2005 – 2015 and served as Vice President of the Diagnostics & Testing team as well as Vice President of the Global Custom Products business focused on oligonucleotides and peptides. 

From 1999 to 2005, Tish was with Applied Biosystems serving as Director, R&D Proteomics & Small Molecule Division with a focus on mass spectrometry.  Tish has enjoyed a career directing multidisciplinary product development in the life science and pharmaceutical markets and has a successful track record managing in both global multinational environments and small entrepreneurial settings. 

Professionally, Tish is the recipient of several scientific achievement awards; she is a published author of both scientific articles and patents.  Tish completed her PhD in Organic Chemistry from The Pennsylvania State University, State College, Pennsylvania, USA. 

James Davis - Non-Executive Director

James Davis - Non-Executive Director

James joined Astorg in 2019 and is a member of the Investment Team. Prior to this, he spent 20 years at ICG where he was Managing Director responsible for investments in the Nordic Region and a member of the Investment Committee.

James started his career at Deloitte where he qualified as a chartered accountant.

James is a graduate of Oxford University.

Judy C Lewent - Non-Executive Director

Judy C Lewent - Non-Executive Director

Judy joined the Board of LGC in July 2021 and is its Chair of the Audit Committee.

Prior to joining the Board, Judy served as the Chief Financial Officer at Merck & Co. from 1990 until her retirement in 2007, where she was responsible for worldwide financial, corporate development and licensing matters as well as for strategic planning. Judy also served as President at Human Health Asia from January 2003 until July 2005.

Judy is currently a director of Motorola Solutions and until May 2021, a Director of GlaxoSmithKline Plc and Thermo Fisher Scientific, Inc. She also served on the Boards of Directors of Motorola, Dell and Quaker Oats. She is a trustee of the Rockefeller Family Trust, a life member of the Massachusetts Institute of Technology Corporation and a member of the American Academy of Arts & Sciences.

Judy earned a Bachelor’s Degree from Goucher College and a Master’s Degree from the MIT Sloan School of Management.

François de Mitry - Non-Executive Director

François de Mitry - Non-Executive Director

François joined Astorg in 2012 and is a member of the Investment team.

He has been involved in a number of transactions including Megadyne, Linxens, IQ-EQ, Flowbird, Audiotonix and Anaqua. Prior to joining Astorg, François was with Intermediate Capital Group Plc from 1997. There, he was appointed Managing Director in 2005, then became progressively more responsible for ICG's investment activities in Mezzanine and Equity worldwide. Previously, he was an Associate Director at the LBO division of Société Générale in London and began his career at the M&A division of HSBC in London.

François graduated from the Institut d'Etudes Politiques de Paris and Université de Paris-Dauphine.

 

Matthew Norton - Non-Executive Director

Matthew Norton - Non-Executive Director

Matthew joined Cinven in 2010 and is a member of its Healthcare sector team. He has been involved in a number of transactions, including Medpace, NPS, Pronet, Sebia, STADA, Labco and Synlab (merged under the Synlab brand), Envirotainer and Ufinet.

Prior to joining Cinven, Matthew worked in the Investment Banking Division of Citigroup in London, advising on M&A and restructuring deals across a range of sectors including consumer, real estate, TMT and healthcare.

Matthew graduated from Imperial College London with a Master’s Degree in Physics.

Supraj Rajagopalan - Non-Executive Director

Supraj Rajagopalan - Non-Executive Director

Supraj joined Cinven in 2004 and leads its Healthcare Sector team. He sits on the firm’s Investment and Executive Committees and has worked on a number of transactions, including Ahlsell, Barentz, Bioclinica, CeramTec, JLA, Medpace, National Seating & Mobility, Phadia, Sebia and STADA. 

Prior to joining Cinven, Supraj was at The Boston Consulting Group, where he worked on projects in the healthcare and financial services sectors. 

Supraj graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. 

Dr Nicolas Roelofs - Non-Executive Director
Nicholas Roelofs

Dr Nicolas Roelofs - Non-Executive Director

Nicolas joined the Board of LGC in April 2016.

Prior to joining the Group, Nicolas served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group (2009 to 2013) and Vice President and General Manager of the Life Sciences Division (2006 to 2009).

Prior to joining Agilent Technologies Inc., Nicolas was with Bio-Rad Laboratories, Inc. (2005 to 2006) and served as the Life Science Group’s Group Operations Officer, heading five business divisions spanning life science and food science. His time at Stratagene Corporation (2001 to 2005) saw him serve as Senior Vice President of Marketing, Sales and Business Development for the first two years and then as Chief Operating Officer.

Professionally, Nicolas is a Global 50 Member and part of the Malaysian Biotechnology International Advisory Panel. He has also served on the Advisory Board of Chemical & Engineering News for the American Chemical Society Magazine. Nicolas completed a Master’s Degree in Organic Chemistry from Iowa State University and has a PhD in Organic Chemistry from the University of Nevada, Reno.

Sebastian Shea - Non-Executive Director

Sebastian Shea - Non-Executive Director

Sebastian is a Portfolio Manager in ADIA’s EMEA Private Equity team. Prior to joining ADIA in 2017, he held positions at G Square Healthcare Private Equity Ltd and Rothschild & Co’s Healthcare team in London.

Sebastian holds a Batchelor’s Degree in Physics and Philosophy from Yale University and an MBA from Columbia Business School.

 

Executive leadership team

Euan O’Sullivan - President and Chief Executive Officer
Euan

Euan O’Sullivan - President and Chief Executive Officer

Euan was appointed President and Chief Executive Officer in September 2021.

After joining LGC in 2007 as a Non-Executive Director, Euan served as Corporate Development Director from July 2010 before being appointed Managing Director of the Standards division in 2012. In 2017, he joined the Board of LGC as an Executive Director and was then appointed Chief Operating Officer (COO) in June 2020.

Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan worked as a Consultant in Accenture’s business strategy practice and within the M&A division of Close Brothers Corporate Finance. Euan is a graduate of University College, Oxford.

Vivid Sehgal - Chief Financial Officer

Vivid Sehgal - Chief Financial Officer

Vivid joined LGC as Chief Financial Officer on 24 January 2022, from Tate & Lyle Plc, a global ingredients and solutions company.

Prior to this, he served as CFO of Delphi Technologies Plc and LivaNova Plc and led both companies through their public listings. Earlier in his career, he held senior management positions in Allergan Inc., Gillette Inc., and GlaxoSmithKline Plc in the US, Europe and the Middle East.

Vivid is a member of the Chartered Institute of Management Accountants and holds a Master’s Degree in Finance from the University of Exeter.

Dr Derek Craston - Chief Scientific Officer

Dr Derek Craston - Chief Scientific Officer

Derek joined the Board of LGC on 1 February 2012 as Chief Scientific Officer.  He continues with his existing role leading LGC's National Measurement Laboratory and Nucleic Acid Therapeutics (NAT) operations.

Derek's responsibilities as CSO include leading the scientific efforts of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Dr. Bharathi Anekella - Executive Vice President and General Manager, LGC Clinical Diagnostics

Dr. Bharathi Anekella - Executive Vice President and General Manager, LGC Clinical Diagnostics

Bharathi joined SeraCare in 2000, which was subsequently acquired by LGC.

Bharathi served as Senior Vice President of Product Development and Technical Operations from 2014 and, in 2021, assumed leadership of LGC Clinical Diagnostics as its Executive Vice President and General Manager.

Prior to joining SeraCare, Bharathi was a lead scientist at DNA Technologies where she developed molecular assays and managed contract manufacturing. She has more than 25 years of experience in technology and product development in infectious diseases, oncology, genetic diseases and recombinant virus.

Bharathi has a PhD in Microbiology from Osmania University, India.

Lewis Cameron - DDS General Manager

Lewis Cameron - DDS General Manager

Lewis joined LGC in early 2021 having spent almost 30 years in pharmaceutical development. He has worked in senior roles for several companies including Lapcorp, Chiltern, Avillion and Clearstone Laboratories.

He has a Batchelor’s Degree in Biology from the University of Edinburgh and an MBA from the IE Business School in Madrid.

Mark Dearden - Managing Director, LGC Biosearch Technologies

Mark Dearden - Managing Director, LGC Biosearch Technologies

Mark was appointed Managing Director, LGC Biosearch Technologies in July 2020.

Having initially joined LGC as a business unit director in 2011, Mark went on to serve as Vice President of Strategy and Marketing for the Genomics Division. In this role, Mark was responsible for the M&A activities, partnering, organic product development and marketing communications activities.

Prior to joining LGC, Mark held diverse international leadership positions in General management, marketing, product management and sales with leading life sciences companies such as GE Healthcare and Thermo Scientific.  Mark has a Batchelor’s Degree from the University of Sydney and an MBA from Warwick Business School.

Michael St. Pierre - Executive Vice President and General Manager, LGC Standards

Michael St. Pierre - Executive Vice President and General Manager, LGC Standards

Michael was appointed Executive Vice President and General Manager, LGC Standards in April 2022. He joined LGC in July 2020 as the Executive Vice President and General Manager of the Analytical Standards business.

Michael has worked in the international chemical industry for over 25 years gaining commercial, operational, innovation and management experience from numerous business leadership roles. Before joining LGC, he was Group Vice President for Sulphur Products and Performance Chemicals at Chemtrade while overseeing customer service, supply chain, transportation and sales functions. Prior to Chemtrade, Michael worked for 15 years for Huntsman Chemical in successive international leadership roles based in North America, Asia and Europe.

Michael holds a Master’s Degree in Chemistry as well as a Batchelor’s Degree in Applied Chemistry from McMaster University, Canada, and an MBA from Queen’s University, Canada.

Michael D Wilson - Senior Vice President, LGC Assure

Michael D Wilson - Senior Vice President, LGC Assure

Mike was appointed Senior Vice President, LGC Assure, in January 2022. 

Having joined LGC in 2018, in the roles of Global Head, Ethical Trade and Responsible Sourcing and Director of Global Business Development for BRCGS, Mike was then appointed Business Director, leading Safefood 360˚ following its acquisition in 2020.

Prior to joining LGC, Mike had 20 years in the global Testing, Inspection and Certification (TIC) sector, where he worked for two global businesses and owned his own inspection and auditing firm.

He holds a qualification in Forestry and a certificate in Marketing.

Lisa Amaya Price - Chief People Officer

Lisa Amaya Price - Chief People Officer

Lisa joined LGC in October 2020 as Chief People Officer.

Lisa’s experience of working with life sciences companies includes Takeda Pharmaceuticals, where she led the organisational design and talent selection related to the company’s acquisition of Shire Pharmaceuticals and was Global Head of Human Resources for Takeda’s vaccine business unit. Before joining Takeda, Lisa served in various positions of increasing responsibility at Biogen, Inc. from 2008 to 2016. 

Most recently, prior to joining LGC, Lisa was SVP, Human Resources at Scholar Rock, Inc., a clinical-stage biotechnology company based in Massachusetts.

Lisa holds an MBA from F.W. Olin Graduate School of Business at Babson College, a Master’s Degree from Simmons College, and a Bachelor's Degree from Bard College.

Manjeet Aujla - Chief Digital and Information Officer

Manjeet Aujla - Chief Digital and Information Officer

Manjeet joined LGC in April 2021 as Chief Digital and Information Officer.

Following his service with the Royal Air Force, Manjeet has enjoyed an extensive career in pharmaceuticals with GlaxoSmithKline. He has a wealth of experience in leading global technology functions across the entire pharmaceutical and vaccine verticals. In addition to technology leadership, Manjeet has extensive experience of managing enterprise-wide business transformation programmes.

Manjeet holds a Bachelor’s Degree in Engineering and a Diploma in Accounting and Finance.

Greer McMullen - General Counsel and Company Secretary

Greer McMullen - General Counsel and Company Secretary

Greer McMullen joined LGC in September 2020 as General Counsel and Company Secretary.

Greer has a wealth of experience spanning executive roles in a number of companies, including GE, The Service Master Company and most recently Coty Inc. 

Greer has operated across a number of different geographies and cultures, in the Americas, Europe and Asia Pacific. He was educated in the UK and France before attending university in the US at Georgetown University School of Foreign Service and then law school at the University of Virginia School of Law.  He is a member of the Virginia Bar.

Sanjeev Rana - Senior Vice President, Corporate Strategy, Development and Communications

Sanjeev Rana - Senior Vice President, Corporate Strategy, Development and Communications

Sanjeev joined LGC in 2019 as Finance Director, M&A.

In March 2021, he was appointed to the role of Senior Vice President, Corporate Strategy, Development and Communications and is responsible for the development of enterprise strategy and inorganic growth efforts, as well as overseeing all aspects of investor relations and corporate communications for LGC.

Prior to joining LGC, Sanjeev gained extensive experience in the life sciences, healthcare and industrials sectors, working for international organisations including Hesira Group Limited, Danaher Corporation, UBS Investment Bank and KPMG.

Sanjeev holds a Batchelor’s Degree in Chemistry from the University of East Anglia and is a qualified Chartered Accountant.


Science advisory board

Dr Ron Cook - Advisor

Dr Ron Cook - Advisor

Ron Cook is an entrepreneurial scientist focused on the development, application and commercialisation of synthetic nucleic acids. He has a Chemistry degree from UC Berkeley, a PhD from the University of Washington, Seattle, Department of Chemistry, and a post-doctorate from the University of California, San Francisco, Department of Microbiology and Immunology.

Ron founded Biosearch, Inc in 1977 to supply synthetic peptides and protein bioconjugates to the research community. In 1980, the production of synthetic nucleic acids propulsed the company to become a leading innovator in oligonucleotide chemistry and a leader in the supply and technology development for synthetic DNA.  In 1982, the company developed the first commercially viable oligo synthesizer (SAM I), which enabled the invention of PCR in 1983. Over the next 30 years, under Ron’s leadership, Biosearch and its descendent entities, participated in the development of many oligo-driven technologies, including PCR, therapeutic antisense oligos, synthetic gene manufacture, sequencing of the human genome, si-RNA and recently, fluorescent probes for genomic analysis and qPCR.   

Ron has published over 30 scientific papers and issued more than 25 patents. Today, Ron is chairman of a number of organisations in the US, Denmark and Germany. He is also co-founder and chairman of Optical Biosystems.

Prof. Duncan Graham - University of Strathclyde

Prof. Duncan Graham - University of Strathclyde

Duncan is the Research Professor of Chemistry and Head of Department for Pure and Applied Chemistry at the University of Strathclyde in Glasgow. 

Duncan obtained his Batchelor’s Degree and PhD in Chemistry from the University of Edinburgh before joining the University of Strathclyde in 1996. He is Editor in Chief of the RSC journal ‘Analyst’ and serves several editorial advisory boards including ‘Chemical Society Reviews’ and ‘Chemical Science’.

Duncan is President of the analytical division of the Royal Society of Chemistry and Chair of the analytical chemistry trust fund. He has published over 250 papers with 16 patents and has supervised over 60 PhD students and 35 postdoctoral researchers.

Duncan’s scientific interests are in using synthetic chemistry to produce sensors that respond to a specific biological species or events as measured by Raman spectroscopy or SERS. 

Dr Sven Kili - Consultant

Dr Sven Kili - Consultant

Sven provides STRATEGIC consulting services to cell and gene therapy organisations focused on business strategy, R&D, clinical development and commercial planning.

Prior to heading his own consultancy, Sven was VP and Development Head for the Gene and Cell Therapy division of GSK where he led the teams developing ex-vivo gene therapies for a variety of genetic disorders. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy clinical and medical activities, he oversaw all UK & Ireland regulatory functions and was the QPPV for the EU.

Sven trained as an orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practice, has grown his expertise in all aspects of cell and gene therapy. In addition to his consulting role, he has a number of other roles, including Board member for CCRM in Canada, Board member for Xintela A.B, Visiting Professor and Steering Committee chair for UCL Cell & Gene Therapy MSc and Chair of the BioIndustry Cell & Gene Therapy Advisory Committee. Sven also serves on specialist committees for the SCB, ASGCT and Alliance for Regen Med. He still maintains his clinical skills in the UK NHS and serves as an ATLS instructor in his spare time. 

Dr Gene Yeo - University of California, San Diego

Dr Gene Yeo - University of California, San Diego

Gene is an expert in the areas of RNA biology and therapeutics, computational biology, genomics and neurological diseases.

He is a Professor of Cellular and Molecular Medicine at the University of California, San Diego (UCSD). He has Batchelor’s Degrees in Chemical Engineering and in Economics from the University of Illinois, Urbana-Champaign, a PhD in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management.

Gene’s research interest is in understanding and manipulating RNA processing in development and disease using induced pluripotent stem cell and murine models. His lab demonstrated in vivo RNA targeting with CRISPR/Cas proteins with proof of concept in repeat expansion disorders and developed enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions. Gene’s lab is an active participant in RNA genomics technology and therapeutics development.

Gene is on the editorial boards of the journals ‘Cell Reports’ and ‘Cell Research’. He is a recipient of the Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011) and the inaugural Early Career Award from the International RNA Society (2017).

Gene is a co-founder of several biotech companies including Locana, Eclipse Bioinnovations, Enzerna and Proteona. He serves or has served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, LGC, Nugen and Ribometrix.